High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
42.93M
-27.88%
-0.217
-49.2%
44.54M
+8.52%
-0.138
-64.14%
48.63M
+6.98%
-0.135
-44.34%
Estimates Revision
The market is revising Upward the revenue expectations for Cryoport, Inc. (CYRX) for FY2025, with the revenue forecasts being adjusted by 1.43% over the past three months. During the same period, the stock price has changed by -4.54%.
Revenue Estimates for FY2025
Revise Upward
+1.43%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-3.59%
In Past 3 Month
Stock Price
Go Down
-4.54%
In Past 3 Month
4 Analyst Rating
Wall Street analysts forecast CYRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYRX is 13.63 USD with a low forecast of 12.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.880
Low
12.00
Averages
13.63
High
15.00
Current: 9.880
Low
12.00
Averages
13.63
High
15.00
UBS
Buy
maintain
$11
2025-11-05
Reason
UBS
Price Target
$11
2025-11-05
maintain
Buy
Reason
UBS raised the firm's price target on Cryoport to $12.50 from $11 and keeps a Buy rating on the shares.
BTIG
NULL -> Buy
maintain
$10 -> $15
2025-09-18
Reason
BTIG
Price Target
$10 -> $15
2025-09-18
maintain
NULL -> Buy
Reason
BTIG raised the firm's price target on Cryoport to $15 from $10 and keeps a Buy rating on the shares. The stock has been under some pressure over the past 2 years, but this is likely due to worries around the Inflation Reduction Act, tariffs, Most Favored Nation, and drug pricing reform risk, and the market appears to be turning the corner, the analyst tells investors in a research note. Cryoport's gross margin and Product revenue growth are also showing good improvement, and the company has well over $400M of cash, the firm added.
KeyBanc
Sector Weight -> Overweight
upgrade
$15
2025-08-06
Reason
KeyBanc
Price Target
$15
2025-08-06
upgrade
Sector Weight -> Overweight
Reason
KeyBanc upgraded Cryoport to Overweight from Sector Weight with a $15 price target following the Q2 beat. The firm believes the cell and gene therapy market is gaining momentum as FDA approved therapies, particularly CAR-Ts, emerge as a significant growth driver. The analyst now has visibility into more consistent results going forward for Cryoport.
Leerink
Market Perform -> Outperform
upgrade
$10 -> $16
2025-08-06
Reason
Leerink
Price Target
$10 -> $16
2025-08-06
upgrade
Market Perform -> Outperform
Reason
Leerink upgraded Cryoport to Outperform from Market Perform with a price target of $16, up from $10. The firm believes the company is positioned to beat estimates on continued cell and gene therapy market services strength. The analyst is also encouraged by recent stabilization in the company's MVE business. Leerink sees "beats and raises" well into 2026 for Cryoport.
Stephens
NULL
to
Overweight
initiated
$13
2025-07-21
Reason
Stephens
Price Target
$13
2025-07-21
initiated
NULL
to
Overweight
Reason
Stephens resumed coverage of Cryoport with an Overweight rating and $13 price target. The firm says the company has a large platform of supply chain solutions for the growing cell and gene therapy industry. Cryoport will benefit as the macro environment normalizes and therapies move through the clinical pipeline, the analyst tells investors in a research note.
BTIG
Buy
downgrade
$13 -> $10
2025-07-07
Reason
BTIG
Price Target
$13 -> $10
2025-07-07
downgrade
Buy
Reason
BTIG lowered the firm's price target on Cryoport to $10 from $13 and keeps a Buy rating on the shares following the firm's survey of biopharma manufacturers. R&D Services budgets will likely face the most risk and headwinds over the next 2 years, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cryoport Inc (CYRX.O) is -15.55, compared to its 5-year average forward P/E of -86.73. For a more detailed relative valuation and DCF analysis to assess Cryoport Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-86.73
Current PE
-15.55
Overvalued PE
118.10
Undervalued PE
-291.56
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
7.60
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
128.59
Undervalued EV/EBITDA
-113.39
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5.21
Current PS
0.00
Overvalued PS
9.07
Undervalued PS
1.35
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
CYRX News & Events
Events Timeline
(ET)
2025-11-04
16:43:58
Cryoport increases FY25 revenue forecast to $170.0M-$174.0M, up from $165M-$172M
2025-11-04
16:42:43
Cryoport Announces Q3 Earnings Per Share of 18 Cents, Below Consensus Estimate of 19 Cents
2025-10-01 (ET)
2025-10-01
08:31:31
Cryoport unveils cutting-edge facility in Louvres, France
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
3.5
11-07NewsfilterCryoport Systems Receives 2025 BioTech Breakthrough Award for "BioServices Innovation of the Year"
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/06d32e33432553cc093c17272879765b7890f16e51f05c2321bdf2562324962e.png)
Preview
3.5
11-06GlobenewswireCryoport Systems Receives 2025 BioTech Breakthrough Award for "BioServices Innovation of the Year"
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/6f1cba2cc62a869643b4a6a255ff3ed10e53e06949e55b2702cebfcd6057099c.jpg)
Preview
9.5
11-05NASDAQ.COMCryoPort, Inc. (CYRX) Announces Q3 Loss but Exceeds Revenue Projections
Sign Up For More News
People Also Watch
FAQ
What is Cryoport Inc (CYRX) stock price today?
What is Cryoport Inc (CYRX)'s business?
What is the price predicton of CYRX Stock?
What is Cryoport Inc (CYRX)'s revenue for the last quarter?
What is Cryoport Inc (CYRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cryoport Inc (CYRX)'s fundamentals?
How many employees does Cryoport Inc (CYRX). have?